Recent advances in ADHD medication
Pro Research Analysisby 
Searched over 200M research papers
Advances in ADHD Medication: Stimulants and Nonstimulants
Recent years have seen significant progress in the pharmacological management of ADHD, with both stimulants and nonstimulants playing important roles. Stimulants, such as amphetamines and methylphenidate, remain the first-line treatment and are available in a wide range of formulations, including longer-acting versions and advanced drug delivery systems that provide more convenient dosing and reduce the risk of misuse and dependence 12348. These innovations allow for better tailoring of treatment duration and help address concerns about abuse .
New Nonstimulant Medications and Expanding Options
Nonstimulant medications have become increasingly important, especially for patients who do not respond well to stimulants or experience side effects. Atomoxetine was the first nonstimulant approved for ADHD, and more recently, viloxazine extended-release (ER) has been approved for both children and adults 156. Other nonstimulants, such as clonidine ER and guanfacine ER, are approved for children and adolescents in the US 16. Several new compounds are under investigation, including centanafadine, solriamfetol, and L-threonic acid magnesium salt, which are currently in Phase 3 trials . Antidepressants like bupropion and vortioxetine, as well as atypical antipsychotics, have also been studied, though they are not yet FDA-approved for ADHD .
Innovative Drug Delivery Systems and Personalized Treatment
Recent trends include the development of new drug delivery systems, such as the methylphenidate transdermal patch and the first transdermal amphetamine patch, which offer unique benefits for personalizing treatment based on individual needs and preferences 35. These innovations help improve adherence and convenience for patients 35.
Nonpharmacological and Device-Based Therapies
While pharmacological treatments remain central, there is growing interest in nonpharmacological therapies and device-based interventions. Digital therapeutics and neurostimulation devices, such as trigeminal nerve stimulation, are emerging as promising options, especially for pediatric ADHD. These approaches can complement or augment medication, offering additional ways to manage symptoms and improve quality of life 56.
Trends in Clinical Trials and Future Directions
Clinical trials over the past two decades have increasingly focused on both pharmacological and nonpharmacological treatments. About 20% of recent ADHD trials have investigated medications, with the rest exploring behavioral, device-based, and alternative therapies . There is ongoing research to develop new medications and improve existing ones, aiming for better efficacy, safety, and tolerability 1710.
Conclusion
Recent advances in ADHD medication include the development of longer-acting stimulants, new nonstimulant drugs, innovative delivery systems, and the integration of digital and device-based therapies. These innovations provide more options for personalized care and address the diverse needs of individuals with ADHD. Ongoing research continues to expand the range of effective treatments, with the goal of improving outcomes and quality of life for patients of all ages 13567810.
Sources and full results
Most relevant research papers on this topic